Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs

5 Mar 2019

Abstract excerpt

prediction of drug efficacy. As such, characterization of environments conducive to achieving the desired pharmacologic outcome is warranted. We recently reported that the clinical CDK4/6 inhibitor palbociclib displays cell type-specific target engagement: Palbociclib engaged CDK4 in cells biologically sensitive to the drug, but not in biologically insensitive cells. Here, we report a molecular explanation for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to Chronic Lymphocytic Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30837298
DOI: 10.1158/1535-7163.mct-18-0755

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor DrugsPMID 30837298Read ↗

Chemoproteomic Evaluation of Target Engagement by the Cyclin-Dependent Kinase 4 and 6 Inhibitor Palbociclib Correlates with Cancer Cell ResponseSemantic proximity Read ↗

Spectrum and Degree of CDK Drug Interactions Predicts Clinical PerformanceSemantic proximity Read ↗

Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017Semantic proximity Read ↗

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclibSemantic proximity Read ↗

Durability of Kinase-Directed Therapies—A Network Perspective on Response and ResistanceSemantic proximity Read ↗

Targeting the Breast Cancer KinomeSemantic proximity Read ↗

Charting the Multi-level Molecular Response to Palbociclib in ER-Positive Breast CancerSemantic proximity Read ↗

The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assaysSemantic proximity Read ↗

Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin ASemantic proximity Read ↗

The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assaysSemantic proximity Read ↗

Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2Semantic proximity Read ↗

Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding InterfaceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.